Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity

Toxicology

Volumn 322, Issue , 2014, Pages 34-42

  Tu, Meijuan ^a   Li, Liping ^a   Lei, Hongmei ^a   Ma, Zhiyuan ^a   Chen, Zhongjian ^b   Sun, Siyuan ^a   Xu, Siyun ^a   Zhou, Hui ^a   Zeng, Su ^a   Jiang, Huidi ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

CYP3A4; Double transfected cells; Hepatotoxicity; Organic cation transporter 1; Retrorsine; Transporters

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 3A4; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC CATION TRANSPORTER 1; QUINIDINE; RETRORSINE; TETRAHYDROPALMATINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME METABOLISM; IC 50; LIVER CELL; LIVER PROTECTION; LIVER TOXICITY; MALE; MDCK CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; RAT;

CYP3A4; DOUBLE-TRANSFECTED CELLS; HEPATOTOXICITY; ORGANIC CATION TRANSPORTER 1; RETRORSINE; TRANSPORTERS;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DOGS; DRUG-INDUCED LIVER INJURY; HEPATOCYTES; HUMANS; HYDROGEN-ION CONCENTRATION; MADIN DARBY CANINE KIDNEY CELLS; MASS SPECTROMETRY; NEOPLASM PROTEINS; ORGANIC CATION TRANSPORTER 1; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; PRIMARY CELL CULTURE; PYRROLIZIDINE ALKALOIDS; RATS; RATS, SPRAGUE-DAWLEY; TRANSFECTION;

EID: 84901630172     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2014.04.007     Document Type: Article

References (45)

1. Ahlin G., Karlsson J., Pedersen J.M., Gustavsson L., Larsson R., Matsson P., Norinder U., Bergström C.A., Artursson P. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J. Med. Chem. 2008, 51:5932-5942.
2. Chen T., Mei N., Fu P.P. Genotoxicity of pyrrolizidine alkaloids. J. Appl. Toxicol. 2010, 30:183-196.
3. Chen Z., Huo J.-R. Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations. Neth. J. Med. 2010, 68:252-260.
4. Chou M.W., Fu P.P. Formation of DHP-derived DNA adducts in vivo from dietary supplements and Chinese herbal plant extracts containing carcinogenic pyrrolizidine alkaloids. Toxicol. Ind. Health 2006, 22:321-327.
5. Dai J., Zhang F., Zheng J. Retrorsine, but not monocrotaline, is a mechanism-based inactivator of P450 3A4. Chem. Biol. Interact. 2010, 183:49-56.
6. Fahrmayr C., König J., Auge D., Mieth M., Fromm M. Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br. J. Pharmacol. 2012, 165:1836-1847.
7. Fletcher M.T., McKenzie R.A., Blaney B.J., Reichmann K.G. Pyrrolizidine alkaloids in Crotalaria taxa from northern Australia: risk to grazing livestock. J. Agric. Food Chem. 2008, 57:311-319.
8. Fu P.P., Xia Q., Lin G., Chou M.W. Genotoxic pyrrolizidine alkaloids - mechanisms leading to DNA adduct formation and tumorigenicity. Int. J. Mol. Sci. 2002, 3:948-964.
9. Fu P.P., Xia Q., Lin G., Chou M.W. Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab. Rev. 2004, 36:1-55.
10. Gao H., Li N., Wang J.Y., Zhang S.C., Lin G. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J. Dig. Dis. 2012, 13:33-39.
11. Giacomini K.M., Huang S.-M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X., Dahlin A., Evers R., Fischer V., Hillgren K.M. Membrane transporters in drug development. Nat. Rev. Drug Discov. 2010, 9:215-236.
12. Gomez-Lechon M., Lahoz A., Gombau L., Castell J., Donato M. In vitro evaluation of potential hepatotoxicity induced by drugs. Curr. Pharm. Des. 2010, 16:1963-1977.
13. Gorboulev V., Ulzheimer J.C., Akhoundova A., UlzheimerTeuber I., Karbach U., Quester S., Baumann C., Lang F., Busch A.E., Koepsell H. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997, 16:871-881.
14. Gordon G.J., Coleman W.B., Grisham J.W. Induction of cytochrome P450 enzymes in the livers of rats treated with the pyrrolizidine alkaloid retrorsine. Exp. Mol. Pathol. 2000, 69:17-26.
15. Gordon G.J., Coleman W.B., Hixson D.C., Grisham J.W. Liver regeneration in rats with retrorsine-induced hepatocellular injury proceeds through a novel cellular response. Am. J. Pathol. 2000, 156:607-619.
16. Hashizume T., Yoshitomi S., Asahi S., Uematsu R., Matsumura S., Chatani F., Oda H. Advantages of human hepatocyte-derived transformants expressing a series of human cytochrome P450 isoforms for genotoxicity examination. Toxicol. Sci. 2010, 116:488-497.
17. Iwai M., Minematsu T., Li Q., Iwatsubo T., Usui T. Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein. Drug Metab. Dispos. 2011, 39:2314-2320.
18. Jonker J.W., Buitelaar M., Wagenaar E., van der Valk M.A., Scheffer G.L., Scheper R.J., Plösch T., Kuipers F., Elferink R.P.O., Rosing H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15649-15654.
19. König J., Zolk O., Singer K., Hoffmann C., Fromm M. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br. J. Pharmacol. 2011, 163:546-555.
20. Kempf M., Reinhard A., Beuerle T. Pyrrolizidine alkaloids (PAs) in honey and pollen-legal regulation of PA levels in food and animal feed required. Mol. Nutr. Food Res. 2010, 54:158-168.
21. Kempf M., Wittig M., Schönfeld K., Cramer L., Schreier P., Beuerle T. Pyrrolizidine alkaloids in food: downstream contamination in the food chain caused by honey and pollen. Food Addit. Contam. A 2011, 28:325-331.
22. Klaassen C.D., Aleksunes L.M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev. 2010, 62:1-96.
23. Koepsell H., Lips K., Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 2007, 24:1227-1251.
24. Kopplow K., Letschert K., König J., Walter B., Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol. 2005, 68:1031-1038.
25. Lin G., Wang J.Y., Li N., Li M., Gao H., Ji Y., Zhang F., Wang H., Zhou Y., Ye Y. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J. Hepatol. 2011, 54:666-673.
26. Liu J., Liu Y., Powell D.A., Waalkes M.P., Klaassen C.D. Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology 2002, 170:55-62.
27. Lu X., Sun D., Chen Z., Ye J., Wang R., Li L., Zeng S., Jianga H. Evaluation of hepatic clearance and drug-drug interactions of luteolin and apigenin by using primary cultured rat hepatocytes. Pharmazie 2011, 66:600-605.
28. Müller F., König J., Hoier E., Mandery K., Fromm M.F. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem. Pharmacol. 2013, 86:808-815.
29. Maeda H., Ota Y., Wang Y., Ramachandran K., Montgomery R.A., Williams G.M., Sun Z. Contribution of extrahepatic small cells resembling small hepatocyte-like progenitor cells to liver mass maintenance in transplantation model of retrorsine-pretreated liver. SpringerPlus 2013, 2:1-11.
30. +/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 2006, 17:2127-2135.
31. Nies A.T., Koepsell H., Damme K., Schwab M. Organic cation transporters (OCTs MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb. Exp. Pharmacol. 2011, 201:105-167.
32. Nies A.T., Koepsell H., Winter S., Burk O., Klein K., Kerb R., Zanger U.M., Keppler D., Schwab M., Schaeffeler E. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009, 50:1227-1240.
33. Otsuka M., Matsumoto T., Morimoto R., Arioka S., Omote H., Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17923-17928.
34. Roeder E. Medicinal plants in Europe containing pyrrolizidine alkaloids. Pharmazie 1995, 50:83-98.
35. Smith L., Culvenor C. Plant sources of hepatotoxic pyrrolizidine alkaloids. J. Nat. Prod. 1981, 44:129-152.
36. Sun S., Chen Z., Li L., Sun D., Tian Y., Pan H., Bi H., Huang M., Zeng S., Jiang H. The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP. Xenobiotica 2012, 42:1197-1205.
37. Sun S., Wang K., Lei H., Li L., Tu M., Zeng S., Zhou H., Jiang H. Inhibition of organic cation transporter 2 and 3 may be involved in the mechanism of the antidepressant-like action of berberine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 49:1-6.
38. Tachibana A., Tateno C., Yoshizato K. Repopulation of the immunosuppressed retrorsine-treated infant rat liver with human hepatocytes. Xenotransplantation 2013, 20:227-238.
39. Tamta H., Pawar R.S., Wamer W.G., Grundel E., Krynitsky A.J., Rader J.I. Comparison of metabolism-mediated effects of pyrrolizidine alkaloids in a HepG2/C3A cell-S9 co-incubation system and quantification of their glutathione conjugates. Xenobiotica 2012, 42:1038-1048.
40. Tu M., Sun S., Wang K., Peng X., Wang R., Li L., Zeng S., Zhou H., Jiang H. Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity. Toxicology 2013, 311:225-230.
41. Wiedenfeld H. Plants containing pyrrolizidine alkaloids: toxicity and problems. Food Addit. Contam. A 2011, 28:282-292.
42. Wiedenfeld H., Edgar J. Toxicity of pyrrolizidine alkaloids to humans and ruminants. Phytochem. Rev. 2011, 10:137-151.
43. Yasujima T., Ohta K.-y., Inoue K., Ishimaru M., Yuasa H. Evaluation of 4', 6-diamidino-2-phenylindole as a fluorescent probe substrate for rapid assays of the functionality of human multidrug and toxin extrusion proteins. Drug Metab. Dispos. 2010, 38:715-721.
44. Zhou S.-F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008, 38:802-832.
45. Zhou S.-F., Xue C.C., Yu X.-Q., Wang G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr. Drug Metab. 2007, 8:526-553.